| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.004 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.17 | 0.004 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.005 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.005 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.005 |